Pharmaceutical studies for the elucidation and prevention of molecule-targeting therapeutic agents-induced acne-like rash in cancer patients

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460633
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Tokyo University of Pharmacy and Life Science
• Principal Investigator: Sato Takashi 東京薬科大学, 薬学部, 教授 (90266891)
• Co-Investigator(Renkei-kenkyūsha): AKIMOTO Noriko 東京薬科大学, 薬学部, 助教 (80297605)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ざ瘡様皮疹 / ゲフィチニブ / 皮脂腺 / 皮脂 / 脂腺細胞 / 抗がん薬

Outline of Final Research Achievements

A treatment of EGF receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib has been reported to frequently exhibit a typical side effect, acne-like rash, in cancer patients. However, there is little evidence in molecular mechanisms of acne-like rash as well as the therapeutic and preventive strategies against the side effect in the skin. In the present study, we have provided novel evidence that 1) EGFR-TKIs are excreted to sebaceous units in the skin of humans, 2) human sebaceous progenitor cells are prepared, 3) EGFR-TKIs augment the sebum production, and 4) pharmacological candidates to suppress the sebum production are found from natural products. These findings are likely to make contributions to the promotion of proper use of EGFR-TKIs as well as other anti-tumorigenic agents and to the appearance care of cancer patients.

Free Research Field

生化学、皮膚科学、細胞生物学